Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nutropin AQ · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nutropin AQ [somatropin (DNA origin) injection] | DRUG | - |
Inclusion Criteria: * Ability of parent or legal guardian to provide written informed consent and, if applicable, pediatric assent and compliance with study assessments for the full duration of the study * Diagnosis of CF by sweat or genetic testing * Between the ages of 5 and 12 years for girls an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
Nutropin AQ is being studied for the treatment of growth restriction in children with cystic fibrosis. It is an investigational small molecule in Phase 2 clinical development for this respiratory condition. The drug is intended to address growth issues that can occur in pediatric patients with cystic fibrosis.
Nutropin AQ is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this drug for the treatment of growth restriction in children with cystic fibrosis.
Nutropin AQ is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. The drug is being studied for the treatment of growth restriction in children with cystic fibrosis, and its Phase 2 trial has been completed.
Nutropin AQ has one clinical trial, identified as NCT00079742, titled "A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis." This Phase 2 trial enrolled 68 participants and has been completed. The study included children aged 5 years and older of all sexes.
Nutropin AQ is a small molecule being studied for growth restriction in children with cystic fibrosis. It is not described as a growth hormone in the available information. The drug is in Phase 2 clinical development and is not approved for any indication.